Google
ELVN — ENLIVEN THERAPEUTICS INC. (Healthcare >> Biotechnology)
ELVN FAQ
What is ELVN's ROE?
ENLIVEN THERAPEUTICS INC. reports a Return on Equity (ROE) of -21.79%.
What is ELVN's dividend yield?
ENLIVEN THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is ELVN's Deepscope Quality Score?
Deepscope rates ELVN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ELVN?
Deepscope's AI Timing Score for ELVN is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ELVN belong to?
ENLIVEN THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 34.71
Price
-0.78
(-2.20%)
Day Change
|
|
|---|
ELVN, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 34.71 |
| PBV / Sector |
4.84 / 4.63
|
| Earning Per Share | -1.56 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
30.76 M
GREAT
|
| Average 1W Daily Value |
38.56 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:23 |
| Symbol | ELVN |
| Name | ENLIVEN THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,194.41 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 6200 Lookout Road, Boulder, CO, United States, 80301
Phone: 720 647 8519
Website: https://www.enliventherapeutics.com
Employees: 61
Sector: Healthcare >> Biotechnology
Description: Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
